10 | 02 | 20Nanoform establishes US subsidiary Nanoform has established Nanoform USA Inc., a wholly owned subsidiary in the US.
13 | 01 | 20Nanoform appoints Head of US Sales Nanoform has appointed Sally Langa as Head of US Sales. The new role will enable Nanoform to continue its rapid growth with a strengthened presence in the US market.
20 | 12 | 19Nanoform files for GMP certification Nanoform has filed for GMP status with the Finnish Medicines Agency, FIMEA. The drug substance application for GMP clinical manufacture certification exemplifies its progress and growth in the last 12 months.
06 | 11 | 19Nanoform wins the CPhI Excellence in Pharma Award for Formulation Nanoform, an innovative medicine enabling nanotechnology company, has won the Excellence in Pharma Award for Formulation at the prestigious CPhI Pharma Awards.
10 | 10 | 19Nanoform nominated for CPhI Award! We are delighted to have been shortlisted as a finalist for the CPhI Award in the Excellence in Pharma: Formulation category.
25 | 09 | 19Nanoform and AstraZeneca Initiate Technology Evaluation Nanoform is delighted to announce the initiation of a technology evaluation of Nanoform’s Proprietary CESS Technology across a range of AstraZeneca’s proprietary pharmaceutical products.
10 | 09 | 19Nanoform strengthens board with appointment of Mads Laustsen Nanoform has appointed Mads Laustsen as a non-executive board member. This appointment will further strengthen the experienced Nanoform board and support the company as it increases its ability to deliver nanonized APIs for global partners across the pipeline from late stage drug discovery to commercial.
03 | 09 | 19Nanoform appoints Mike Rea as Strategic Innovation Advisor Nanoform has appointed Mike Rea as its Strategic Innovation Advisor. The role will involve working closely with Nanoform to maximise the value its proprietary nanonization technology can deliver to pharmaceutical partners and patients globally.
10 | 07 | 19Nanoform appoints Director of Investor Relations following international growth Nanoform has appointed Henri von Haartman as Director of Investor Relations. The newly created role will enrich investor relations as Nanoform seeks to further its shareholder base and continue its international growth, including expansion into the US market.
03 | 07 | 19Nanoform continues strategic growth with €10 million private placement Nanoform announced the completion of a private placement totaling €10 million, with Ilmarinen Mutual Pension Insurance Company and Mandatum Life Insurance Company (Sampo Group) acting as anchor investors.
27 | 06 | 19Nanoform announces major rebrand Nanoform has unveiled a new brand identity and website. The evolution of Nanoform’s brand reflects how the company is using innovation to transform the pharmaceutical industry and support its global partners as they develop life-changing medicines.
30 | 05 | 19Our CCO, Christian Jones, interviewed at EBD Group’s BIO-Europe Spring 2019. Our CCO, Christian Jones, recently discussed the advantages of our nanonization services with Mike Ward at EBD Group’s BIO-Europe Spring 2019. Watch the Scrip video to learn more: